X IBD’s proprietary rating identifies share price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock’s price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they launch their biggest runs.
Heron Therapeutics has climbed more than 5% past a 17.55 entry in a first-stage cup with handle, meaning it’s now out of a proper buy range. Look for the stock to create a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
In terms of top and bottom line numbers, Heron Therapeutics has posted rising EPS growth in each of the last four reports. Sales gains have been less impressive, coming in at 0% in the latest report.
Heron Therapeutics earns the No. 47 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND) and Vertex Pharmaceuticals (VRTX) are among the top 5 highly rated stocks within the group.